Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease
出版年份 2023 全文链接
标题
Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease
作者
关键词
-
出版物
Cardiovascular Diabetology
Volume 22, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-01-31
DOI
10.1186/s12933-023-01752-4
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial
- (2023) Kausik K Ray et al. Lancet Diabetes & Endocrinology
- Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment
- (2022) David Kallend et al. Journal of Clinical Lipidology
- Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia
- (2022) M Doortje Reijman et al. European Journal of Preventive Cardiology
- Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis
- (2022) Nihar R. Desai et al. American Journal of Cardiovascular Drugs
- Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol
- (2022) Essie Samuel et al. ANNALS OF PHARMACOTHERAPY
- PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis
- (2022) Xing Wang et al. Cardiovascular Diabetology
- Considerations and recommendations for assessment of plasma protein binding and drug–drug interactions for siRNA therapeutics
- (2022) Sara C Humphreys et al. NUCLEIC ACIDS RESEARCH
- An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study
- (2022) David Kallend et al. CTS-Clinical and Translational Science
- 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
- (2022) Donald M. Lloyd-Jones et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials
- (2022) Christina Reith et al. LANCET
- Network Meta‐Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid‐Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low‐Density Lipoprotein Cholesterol
- (2022) Peter P. Toth et al. Journal of the American Heart Association
- Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)
- (2022) Maciej Banach et al. Cardiovascular Diabetology
- Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis
- (2021) R. Scott Wright et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials
- (2021) Emily Herrett et al. BMJ-British Medical Journal
- The Nonclinical Disposition and PK/PD Properties of GalNAc-conjugated siRNA Are Highly Predictable and Build Confidence in Translation to Man
- (2021) Robin McDougall et al. DRUG METABOLISM AND DISPOSITION
- 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
- (2021) Frank L J Visseren et al. EUROPEAN HEART JOURNAL
- Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies
- (2021) Bhavani Shankara Bagepally et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
- (2020) Jan Borén et al. EUROPEAN HEART JOURNAL
- Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1
- (2020) Ulf Landmesser et al. CARDIOVASCULAR RESEARCH
- Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia
- (2020) G. Kees Hovingh et al. CIRCULATION
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Clinician Knowledge and Statin Beliefs With Statin Therapy Use and Lipid Levels (A Survey of US Practice in the PALM Registry)
- (2019) Angela Lowenstern et al. AMERICAN JOURNAL OF CARDIOLOGY
- Patient‐Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry
- (2019) Corey K. Bradley et al. Journal of the American Heart Association
- Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries
- (2019) Guy De Backer et al. ATHEROSCLEROSIS
- Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials
- (2019) Paul Guedeney et al. EUROPEAN HEART JOURNAL
- The patient journey with proprotein convertase subtilisin/kexin type 9 inhibitors in community practice
- (2019) Corey K. Bradley et al. Journal of Clinical Lipidology
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels
- (2019) Kausik K. Ray et al. JAMA Cardiology
- Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies
- (2019) R. Scott Wright et al. MAYO CLINIC PROCEEDINGS
- Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1
- (2018) Kausik K. Ray et al. CIRCULATION
- Patient-reported adherence to statin therapy, barriers to adherence, and perceptions of cardiovascular risk
- (2018) Vicki Fung et al. PLoS One
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab
- (2018) Arman Qamar et al. JAMA Cardiology
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years
- (2017) Michel Farnier et al. Journal of Clinical Lipidology
- Structural Foundations of RNA Silencing by Argonaute
- (2017) Jessica Sheu-Gruttadauria et al. JOURNAL OF MOLECULAR BIOLOGY
- Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction
- (2017) Maria-Corina Serban et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention
- (2017) Erin A. Bohula et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 Inhibitors
- (2017) Mark A. Hlatky et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oligonucleotide Therapeutics — A New Class of Cholesterol-Lowering Drugs
- (2017) Anastasia Khvorova NEW ENGLAND JOURNAL OF MEDICINE
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials
- (2017) Stanley T. Crooke et al. Nucleic Acid Therapeutics
- Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol
- (2017) Robert P. Giugliano et al. JAMA Cardiology
- Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents
- (2016) Paul M Ridker et al. EUROPEAN HEART JOURNAL
- Association Between Low-Density Lipoprotein Cholesterol–Lowering Genetic Variants and Risk of Type 2 Diabetes
- (2016) Luca A. Lotta et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Interpretation of the evidence for the efficacy and safety of statin therapy
- (2016) Rory Collins et al. LANCET
- Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients
- (2015) Olivier Descamps et al. ATHEROSCLEROSIS
- Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability and Risk of Cardiovascular Outcomes
- (2015) Sripal Bangalore et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- PCSK9
- (2014) Nabil G. Seidah et al. CIRCULATION RESEARCH
- Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
- (2014) Jayaprakash K. Nair et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events
- (2014) S. Matthijs Boekholdt et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
- (2013) Kevin Fitzgerald et al. LANCET
- Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol
- (2011) Judith Hsia et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Medication Adherence: WHO Cares?
- (2011) Marie T. Brown et al. MAYO CLINIC PROCEEDINGS
- PCSK9R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease
- (2010) Marianne Benn et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The LDL Receptor
- (2009) Joseph L. Goldstein et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
- (2009) J. C. Y. Chan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
- (2008) Ahmed Zaid et al. HEPATOLOGY
- Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
- (2008) M. Frank-Kamenetsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started